Preet Lakhani has completed MBBS from Pramukh Swami Medical College, Karamsad, Gujarat, INDIA and MD in Pharmacology and Therapeutics from King George’s Medical University, Lucknow, INDIA. He has published more than 20 papers in reputed journals.
Abstract
Insulin degludec is supplied under trade name Tresiba, is an ultra long acting basal insulin which can be used by people with type 1 or type 2 diabetes. Tresiba is suitable for use in treating patients of ages 18 years and older with either type 1 diabetes or type 2 diabetes. Tresiba is taken by subcutaneous injection once daily. One of the benefits of insulin degludec is that it offers much greater flexibility over when doses can be taken. The insulin lasts for up to 42 hours and that allows doses to be taken at different times of day, if needed, without impacting on blood glucose control. This means there is significantly more room varying times of doses to suit your lifestyle. Research studies used to investigate the effectiveness of the drug also showed that Tresiba reduced the risk of nocturnal hypoglycemia, in people with type 1 and type 2 diabetes, in comparison with Lantus (insulin glargine). Trials also noted a reduction in overall hypoglycemia for Tresiba compared with Lantus within patients with type 2 diabetes. Tresiba may not be suitable for people that experience reactions to glycerol, metacresol, phenol or zinc acetate. Tresiba is different to most other insulin available in that it is available in two different strengths. Standard strength 100 units/mL Double strength 200 units/mL
